Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Messoud AshinaStewart J TepperJan Lewis BrandesUwe ReuterGuy P BoudreauMark WeatherallAndreas R GantenbeinDavid DoležilJan KlattAndrea WangAnanda Krishna KaranamSunfa ChengDaniel D MikolPublished in: Headache (2022)
The long-term treatment with erenumab was well tolerated and showed sustained efficacy in patients with CM in whom prior preventive treatments had failed, with numerically greater treatment effects for 140 mg versus 70 mg.
Keyphrases